Nicotinamide → (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal

HRID 1486359

反応式

HRID 1486359 の反応式
CC(C)=CO[Si](C)(C)C.C[C@H]1C2(C(C)=C3C(C4C(C3)C3(C)C(CC(CC3)=O)=CC4)CC2)O[C@@H]2CC(C)CN(CCNC(CCCCCNC(CCC3C=CC=CC=3)=O)=O)C12.CC1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C(O)=O.C[C@H](NC(CC1C=C(F)C=C(F)C=1)=O)C(N[C@H](C(OC(C)(C)C)=O)C1C=CC=CC=1)=O.CC[C@@H]([C@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC(CNC([C@@H](NC(CNC([C@@H](N)CC1NC=NC=1)=O)=O)CCC(O)=O)=O)=O)[C@H](O)C)=O)CC1C=CC=CC=1)=O)[C@H](O)C)=O)CO)=O)CC(O)=O)=O)CC(C)C)=O)CO)=O)CCCCN)=O)CCC(N)=O)=O)CCSC)=O)CCC(O)=O)=O)CCC(O)=O)=O)CCC(O)=O)=O)C)=O)C(C)C)=O)CCCNC(N)=N)=O)CC(C)C)=O)CC1C=CC=CC=1)=O)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(NCC(N1[C@H](C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(N2[C@H](C(N3[C@H](C(N4[C@H](C(N[C@H](C(N)=O)CO)=O)CCC4)=O)CCC3)=O)CCC2)=O)C)=O)=O)CO)=O)CO)=O)CCC1)=O)=O)=O)CC(N[C@@H]1O[C@H](CO)[C@@H]([O:175][C@@H:176]2[O:181][C@H:180]([CH2:182][O:183][C@@]3(C(O)=O)O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)[C@H:179]([OH:205])[C@H:178]([OH:206])[C@H:177]2[OH:207])[C@H](O)[C@H]1NC(C)=O)=O)=O)CCCCN)=O)CC(C)C)=O)CC1C2C=CC=CC=2NC=1)=O)CCC(O)=O)=O)C.C(N)(=O)C1C=CC=NC=1>>[O:175]=[CH:176][C@@H:177]([C@H:178]([C@@H:179]([C@@H:180]([CH2:182][OH:183])[OH:181])[OH:205])[OH:206])[OH:207]

参加物

7

反応物 6

HCID 936Nicotinamide2 回HCID 99685Isobutyraldehyde trimethylsilyl enol ether3 回HCID 444795Retinoic AcidHCID 5311272Dapt2 回HCID 16760383N-[2-[(3'R,7'aR)-3',6',10,11b-tetramethyl-3-oxospiro[1,2,4,6,6a,6b,7,8,11,11a-decahydrobenzo[a]fluorene-9,2'-3,3a,5,6,7,7a-hexahydrofuro[3,2-b]pyridine]-4'-yl]ethyl]-6-(3-phenylpropanoylamino)hexanamide2 回HCID 49862879CID 498628792 回

生成物 1

HCID 107526(2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal

実験手順

Cells were reprogrammed according to Example 11, and were then cultured in DMEM/F12, 100 ng/ml activin A, 25 ng/ml Wnt3a, 0.01% recombinant HSA, 1×ITSE for 1 day, followed by DMEM/F12, 100 ng/ml activin A, 0.01% recombinant HSA, 1×ITSE for 2 days, followed by DMEM/F12, 50 ng/ml FGF10, 0.25 μM KAAD-cyclopamine, 0.01% recombinant HSA, 1×ITSE for 3 days, followed by DMEM/F12, 1% B27, 2 μM all-trans retinoic acid, 50 ng/ml FGF10, 0.25 μM KAAD-cyclopamine for 4 days, followed by DMEM/F12, 1% B27, 1 μM γ-secretase inhibitor DAPT, 50 ng/ml exendin-4, 10 nM betacellulin, 10 mM nicotinamide for 2 days, followed by DMEM/F12, 50 mg/L ascorbic-acid-2-phosphate, 1% B27, 1 μM γ-secretase inhibitor DAPT, 50 ng/ml exendin-4, 50 ng/ml IGF-1, 50 ng/ml HGF, 10 nM betacellulin, 10 mM nicotinamide for 6 days to generate glucose-responsive insulin-producing cells (FIG. 5A). The resulting cells can be used in vitro or in vivo for screening bioactive molecules for the study of diabetes or for the development of therapeutics for diabetes.

後処理

  1. customfor 1 day
  2. customfor 2 days

出典と根拠

ORDレコード
ord-b37f66fc11ba448e86674f1bc8ce2d4a
出典データセット
uspto-grants-2016_08
特許番号
US09422577B2

関連ノート

読み込み中…